Welcome to our dedicated page for McKesson news (Ticker: MCK), a resource for investors and traders seeking the latest updates and insights on McKesson stock.
McKesson Corporation (NYSE: MCK) is a diversified healthcare services and pharmaceutical distribution company that regularly issues news and updates relevant to investors, healthcare partners, and other stakeholders. The company describes itself as dedicated to advancing health outcomes for patients everywhere, partnering with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services that support access to quality care.
The McKesson news feed typically features announcements about quarterly and annual financial results, earnings release dates, and related investor webcasts. These updates often include information about fiscal guidance, long-term financial targets, and commentary on strategic priorities and business outlook shared during events such as Investor Day.
In addition to earnings and guidance, McKesson’s news includes Board actions such as dividend declarations, reflecting decisions on returning capital to shareholders. The company also issues releases on organizational and segment reporting changes, including the introduction of its North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions segments, along with portfolio developments like planned separations or divestitures.
McKesson may also appear in third-party announcements highlighting distribution agreements and collaborations that illustrate its role in pharmaceutical distribution and healthcare services. Such items can show how McKesson supports access to therapies through its distribution networks and healthcare supply chain capabilities.
For readers tracking MCK news, this page provides a centralized view of financial announcements, strategic updates, capital allocation decisions, and partnership-related developments. Regularly reviewing these items can help investors and observers understand how McKesson communicates its performance, segment evolution, and strategic focus within the healthcare and wholesale trade landscape.
McKesson (NYSE: MCK) has released its fiscal 2025 first quarter financial results, which are now available on the company's Investor Relations website. McKesson will host a live webcast of the earnings conference call for investors on Wednesday, August 7th at 4:30 PM ET to review these results. The audio webcast, earnings press release, financial tables, and slide presentation will be accessible on McKesson's Investor Relations website. This platform also provides information about upcoming events for the investor community.
McKesson (NYSE:MCK) has announced a 15% increase in its quarterly dividend to $0.71 per share, up from $0.62 in the previous quarter. The dividend will be payable on October 1, 2024, to stockholders of record on September 2, 2024. This marks McKesson's eighth consecutive annual dividend increase, reflecting the company's confidence in its business fundamentals and financial strength. CEO Brian Tyler emphasized McKesson's commitment to a disciplined capital deployment strategy, focusing on growth and shareholder value creation. The dividend hike underscores the company's strong balance sheet and robust free cash flow generation capabilities.
McKesson (NYSE: MCK) is set to release its first quarter fiscal 2025 financial results on August 7, 2024, after market close. A live webcast of the earnings conference call will be held at 4:30 PM Eastern Time, available on McKesson’s Investor Relations website. The webcast will cover financial results, including earnings release, financial tables, and a slide presentation.
McKesson announced the election of Dr. Deborah Dunsire to its board of directors, effective June 3, 2024. Dr. Dunsire, with over 30 years of experience in the biopharmaceutical and oncology sectors, will also serve on the Compensation and Talent Committee and Finance Committee. She recently retired as CEO of H. Lundbeck A/S and has held leadership roles at XTuit Pharmaceuticals, FORUM Pharmaceuticals, and Millennium: The Takeda Oncology Company.
Meanwhile, current board members Linda Mantia and Susan Salka will not stand for re-election at the 2024 Annual Meeting of Shareholders. The board size will reduce to 11 members, 10 of whom will be independent. McKesson's board chair, Donald Knauss, expressed gratitude for their contributions.
McKesson (NYSE: MCK) has reported its fiscal 2024 fourth quarter financial results. The earnings conference call for investors will be held today, May 7th. The company's financial results, along with a slide presentation, can be accessed on McKesson's Investor Relations website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.